Iron and Retinopathy of Prematurity (ROP) - Trial NCT05133999
Access comprehensive clinical trial information for NCT05133999 through Pure Global AI's free database. This phase not specified trial is sponsored by Assistance Publique - Hôpitaux de Paris and is currently Recruiting. The study focuses on Retinopathy of Prematurity. Target enrollment is 175 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Plasma determination of iron, transferrin and ferritin
Observational
biological
Sponsor & Location
Assistance Publique - Hôpitaux de Paris
Timeline & Enrollment
N/A
Apr 28, 2022
Sep 01, 2024
Primary Outcome
ROP screening,Levels of transferrin saturation in plasma at 1 week of life
Summary
The purpose of this study is to determine whether increased transferrin saturation in plasma
 (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP
 development and severity.
 
 Preterm infants born at 31 week's post-menstrual age (PMA) or ≤1250g of birth weight will be
 included. Iron parameters in plasma will be measured during the first month of life.
 Retinopathy of prematurity (ROP) will be screened as currently recommended. The relationship
 between plasma iron parameters and ROP development and/or severity will be established.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05133999
Non-Device Trial